BioWorld examines a $430 million deal between Sweden's Medivir and Tibotec to develop new polymerase inhibitors. They'll jointly screen libraries for nucleoside analogues that show anti-HCV activity in vitro. And once a compound is identified, Tibotec will take over development and keep marketing rights outside of the Nordic countries. Medivir gets €5 million up front and up to €272 million in milestones if two products reach the market. Researchers for the two companies already have an HCV compound in development. BioWorld also notes that Anadys has a competing therapy being prepared for a Phase I trial that targets HCV viral replication.
- here's the release [1] on the deal
- read the report [2] from BioWorld
Links:
[1] http://www.fiercebiotech.com/press-releases/medivir-ab-broadens-its-hepatitis-c-collaboration-tibotec-entering-partnership-field-
[2] http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=47647